Decontamination wipes supplier Hero Wipes revealed on Tuesday that its Hero Wipes products can now remove up to 99.7% of lead contaminants from skin as well as up to 90% of known carcinogens found in soot.
Public safety professionals, including firefighters and law enforcement personnel, are put at great risk daily from exposure to cancer-causing carcinogens. Firefighters responding to structure fires are exposed not only to potentially carcinogenic soot but lead contaminants coming from household furnishings, carpets and appliances, exposure of gunshot residue as well as lack of proper decontamination.
Assembled in the USA and EWG verified, Hero Wipes has been formulated, tested and proven to remove carcinogenic soot and lead contaminants in the same wipe.
Launched in 2017, Hero Wipes is the first on-scene decontamination wipe to have its unique formulation, a patent-pending blend of ingredients that works to isolate harmful toxins and carcinogens, scientifically tested for effectiveness in their removal. Hero Wipes is proven effective to remove up to 90% of benzopyrene, commonly found in soot and up to 69% of TCEP, the most common toxic flame retardant, in just a single swipe.
Imugene announces Azer-cel Phase 1b clinical trial data
CARsgen successfully defends European GPC3 CAR-T patent
IGI and AbbVie enter global licensing agreement for ISB 2001
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Exact Sciences secures Medicare coverage for Oncodetect MRD test in colorectal cancer
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
Celltrion USA launches denosumab biosimilars STOBOCLO and OSENVELT (denosumab-bmwo) in US
HotSpot Therapeutics presents small molecule CBM signalosome inhibitor program data
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer